6-K

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2017

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant's Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 2100

Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1      A Slide Presentation for Investors – February 2017.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 6, 2017 EVOGENE  LTD.(Registrant)By: /s/ Alex Taskar——————————————Alex Taskar Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	A Slide Presentation for Investors – February 2017.

4

EX-99.1

Exhibit 99.1

 Introduction to Evogene  February 2017  Ofer Haviv, President & CEO 

 Safe Harbor statement  2  This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.  The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.  

 Table of contents   Introduction Our technologyApplications and product programsSummary of investment highlights   3 

 Introducing Evogene  4    We are… A leading biotechnology company for the improvement of crop productivity and performance, addressing the world’s increasing demand for food, feed and fuel   

 Farmer’s needs  5  Farmer’s main inputs  Fertilizers  Agro-technical  Seeds  Ag-Chemicals        Ag-Biologicals  Precision tools    Farmer’s target – maximize profit Increase crop yield  Reduce loses from stresses Minimize input expenses   

 6  The opportunityA dire need for innovation    Crops’ full yield potential - yet to be captured Insect control - resistance to available commercial traits   Extra yield of up to 60% - significant potential yet to be capturedResistance to available commercial solutions  Emerging as promising tool to drive productivity – mainly due to microbiome & data revolutionStability limits applicability of existing products  Seeds - $37B1  Ag-Chemicals - $56B2  Ag-Biologicals - $3B3    1 Source: Phillips McDougall , 20162 Source: Phillips McDougall, 20153 Source: Research & Markets, 2016  

 Evogene 'at a glance’  7  An innovative, predictive discovery technology - applied to identify:Genetic elements for improved seedsChemical compounds for innovative Ag-ChemicalsMicrobes for novel Ag-BiologicalsStrategic collaborations with world-leading agriculture companies - including BASF, Bayer, DuPont, Monsanto, SyngentaRevenue model - based on licensing agreements, which typically include three main revenue streams:R&D payments - short termMilestone payments - mid termRoyalties from product sales - longer termFinancial fundamentals -Cash position - $93 million (September 30th, 2016) Projected cash use for 2016 - ~$15 millionListed on TASE (2007) and NASDAQ (2013)    Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  7 

   Evogene 'at a glance’  7  An innovative, predictive discovery technology - applied to identify:Genetic elements for improved seedsChemical compounds for innovative Ag-ChemicalsMicrobes for novel Ag-BiologicalsStrategic collaborations with world-leading agriculture companies - including BASF, Bayer, DuPont, Monsanto, SyngentaRevenue model - based on licensing agreements, which typically include three main revenue streams:R&D payments - short termMilestone payments - mid termRoyalties from product sales - longer termFinancial fundamentals -Cash position - $93 million (September 30th, 2016) Projected cash use for 2016 - ~$15 millionListed on TASE (2007) and NASDAQ (2013)    Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  7 

 Our revenue & business models  8   R&D payments  R&D funding by partner   Milestone fees  Additional payments received upon achieving predetermined objectives   Royalties  Percentage of product sales by partner  Collaboration timeline  Early collaboration model  Collaboration prior to initiating product discovery and development activity  Late collaboration models  Collaboration following internal product discovery and early development    Advanced development & registration    Discovery  Early development  Commercialization        RD  M  R  Revenue model  RD  M  M  M  R    E    L1,2  Business model    E    L1    L2 

 Value creation per product program  9  Collaboration timeline    Advanced development & registration    Discovery  Early development  Commercialization        RD  M  M  M  R    E    L1    L2      Value (illustration)                  Over 10 majorproduct programs  

 Table of contents   Introduction Our technologyApplications and product programsSummary of investment highlights   10 

 11  Technology platform    Interconnected Data HubComputational integration of ‘Big Data’ - currently four interconnected databases    Science Multidisciplinary scientific approachdriving our R&D          Dedicated ‘Big Data’On-going accumulation - public resources and problem-tailored experiments  Driving Ag Innovationvia predictive biology    Analysis platformsProprietary algorithms and modules to prioritize the best product candidates    Chemical discovery    Gene optimization     Toxin discovery    Gene discovery     Stack discovery     Target discovery 

 12  Plant validation systemsProviding proof for our predictions 

 13  Technology platformImplementation pathways  13  Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  Platform outputs:  Basis for development of innovative products 

 Table of contents   Introduction Our technologyApplications and product programsSummary of investment highlights   14 

 15  15  Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  Platform outputs:  Basis for development of innovative products  Application pathways   

 Improved seeds - market and unmet needs  16  ~$37B* in 2015    Innovation potential  Basic seed  Seed traits           $0.5B  $3.2B  Insect resistance  $1.5B  $3.5B  Herbicide tolerance  $1.2B  $1.5B  Yield  $0.45B  $0.65B  Drought tolerance  $1B  $1B  Disease resistance  Corn  Soy  Examples – trait values   Existing Products  Potential yet tobe captured      Broad commercial potential for bringing ‘breakthrough’ traits to the seed market   * Source: Phillips McDougall , 2015  Biotech Seeds 

 17  Improved seeds - activities and achievements  Product trait programs - focus on corn, soy, wheat, cotton and canola Yield and abiotic stress – since 2004Disease resistance - since 2007Insect resistance – since 2014Main achievements - Most advanced gene in Phase II of developmentCollaborations with industry leadersStrong IP portfolio - over 4000 genes under patent protectionOver 1000 genes under target crop validation by partners  Overview  Traits  Yield  Abiotic stress  Insect resistance  Diseases resistance    Improvedseeds  Example: Monsanto-Evogene collaboration  Collaboration period - 8 yearsObjective - improved seeds via biotechnologyCrops - Corn, soybean, cotton, canolaTraits - Yield, drought tolerance, fertilizer utilizationInsect resistance – Fusarium resistance in cornKey terms - R&D and up-front payments - total c.$68MMilestone payments + royalties from sales$30M equity investment (including $12M in IPO)  Gene discovery and trait optimization  Development and commercialization  Model plant validation  Target plant validationand development          Computational discovery  Partners 

 18  Improved seeds - selected results        Genes demonstrated potential to achieve yield enhancement in target crops  Additional optimization & development towards phase 2    Pathforward  Further optimization and validation in plants towards licensing agreement  Yield  Insect resistance (internal program)  Abiotic stresses  Internal program  collaboration  Novel toxins showed activity against Lepidoptera and Coleopteran insects    Pathforward 

 19  Improved seeds - upcoming value drivers  Improvedseeds    Trait    Gene advancement - Gene advancement within early development (phase 1)Gene advancement to advanced development (phase 2)  Toxin advancement - optimization and licensing -Entry into strategic, product development collaborationToxin advancement within discovery – including optimization and testing in target cropsToxin advancement to early development (phase 1)      Yield  Disease Resistance  Insect Resistance  Gene advancement - Gene advancement within early development (phase 1)Gene advancement to advanced development (phase 2)  Abiotic stress  Discovery  Early Development  Advanced development & registration  Commercialization 

 20  Application pathways  20  Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  Platform outputs:  Basis for development of innovative products   

 21  ~$37B* in 2015    Innovation potential  Key challenge - finding the next generation of novel herbicide  Herbicides  Insecticides  Fungicides  Others  Glyphosate - leading herbicide with >$5B sales, yet broadly increasing weed resistance  Dire need for novel herbicides due to increasing resistance   Source - International Survey of Herbicide Resistant Weeds, www.weedscience.org/graphs/soagraph.aspx (2013)  * Source: Phillips McDougall , 2015  Innovative Ag-Chemicals - market and unmet needs 

 Innovative Ag-Chemicals - activities & achievements  Product programs – Novel herbicides with new Mode of Action (MOA) - since 2013Main achievements – Strategic collaboration with BASF (signed in 2015)Discovery and validation in plants of several novel herbicide targets Tens of discovered small molecules showing potential as active ingredient in novel herbicide  Overview    inhibition  Herbicide targetA macro-molecule within the weed essential for its life  Herbicide chemicalInhibiting target leads to weed death  Weeds  Example: BASF-Evogene collaboration  Collaboration period - 3 yearsObjective - herbicides with new MOA Activities - Evogene to identify novel targets and target-linked chemicals candidatesBASF to screen & validate the candidate chemicals and further develop successful candidates towards commercial products    InnovativeHerbicide  Chemical screens   Target and chemical candidates discovery  Screening, development and commercialization  Computational target & chemical discovery    Targets &chemicals  Chemicalhits  Development,regulation& registration        22 

 Targets successfully validated in plants   Chemicals displayed herbicide activityagainst weeds   Innovative Ag-Chemicals - selected results  23  Advancement of targets and chemical hits – optimization and additional plant testing    Path forward  *Prior to optimization  * Results from Evogene’s internal activity    

 Innovative Ag-Chemicals - upcoming value drivers  24  InnovativeAg-Chemicals  Product    Discovery  Early Development  Advanced development & registration  Commercialization  Chemical hit advancement - Advanced hits - following optimization Initial leads - optimized hits with desired plant efficacy Collaborations -Expand existing or entry into additional collaborations  Insecticides  Consider entry into new segmentsDiscovery of novel insecticides/ fungicides    Herbicides    Fungicides 

 25  Application pathways  25  Innovative discovery technology  Improved Seeds  InnovativeAg-Chemicals  NovelAg-Biologicals  Geneticelements  Microbes  Chemical compounds  Platform outputs:  Basis for development of innovative products   

 26  ~$3.2B* in 2015    Innovation potential  Development of “next generation” Ag-Biological products  * Source: Phillips McDougall , 2015    ~$9B  ~$3.2B  E  Source – 2020 estimation based on integrated information of BCC Research, marketsandmarkets, Agropages and Phillips McDougall   Relatively short time and low investment to marketNeed for novel solutions with stable performanceMicrobiome a promising source for innovation, now accessible via maturing technologies  Novel Ag-Biologicals - market and potential  Bio-stimulats  Bio-pesticides 

 27  Novel Ag-Biologicals - activities and achievements   Product programs - Bio-stimulant (mainly yield and abiotic stress) in corn, soy and wheat – since 2015Main achievements - 10’s of microbes showing consistent improvement of yield traits in greenhouse and fieldEstablishment infrastructure for product research and development - computational, tailored OMIC experiments, plant assays, formulation and fermentation 2OK isolated microbes from unique sourcing samples, with > 10K sequenced genomes   Overview  Crops  Product  Bio-stimulant  X  Internal Bio-stimulant discovery & development program  Novel Biostimulant  Internal Evogene program - including downstream activityLicense out to partner – late collaboration modelExpected time to product - ~5 years  Discovery  Early Development12 months  Development stage 112-18 months  Development stage 212-18 months  Hit    Team    Lead    Pre-commercializtion24 months  Pre Product    Product    Current Status   

 28  Novel Ag-Biologicals - selected results  10’s of microbial Hits displaying positive results in corn field trials  EVO-0685  No treatment   Example: EVO-0685 – improved ear size and weight at harvest resulted with 17% increase of yield per plant  Combination of microbial hits, additional testing along with product development activities (upscale, fermentation & formulation)  Ears at harvest      Path forward   

 Novel Ag-Biologicals - upcoming value drivers  Product    Discovery  Early Development  Advanced development & registration  Commercialization  Bio-stimulants  Bio-pesticides   Progress to advanced development - Advance Hits to Leads based on consortia (microbial team)Field testing & optimization development activity (fermentation & formulation) for Leads       Consider entry into new segmentsDiscovery of novel microbial strains for bio-pesticides  NovelAg-Biologicals  29 

 Table of contents   Introduction Our technologyApplications and product programsSummary of investment highlights   30 

 Investment highlights  5  2  3  4  Strong balance sheet  1  Engine for next generation product development targeting multi-billion dollar ag markets   Unique technology platform, combining expertise in plant science and cutting-edge computational tools  Diversified product portfolio with multiple paths to milestone payments and royalties from commercialization   Innovation partner of choice for industry leaders  31 

 Thank you.  Contact:investors@evogene.comT: +972 8 931 1964